Kazia Therapeutics Limited. KZIA
Annual
Quarterly
No annual revenue total was found in Kazia Therapeutics Limited.'s SEC filings.
Kazia Therapeutics Limited. (KZIA) files with the SEC under industry code 2834, Pharmaceutical Preparations.
Revenue
—
Net income
—
Operating cash flow
—
Free cash flow
—
EPS
—
Dividend per share
None
Shares outstanding
809.42M
+143.2% vs prior year
Net cash
—
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KZIA (Nasdaq)
- Fiscal year ends
- June 30
- Incorporated in
- Australia
- Headquarters
- Sydney Nsw
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1075880
- Former names
- NOVOGEN LTD (until Nov 17, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 6-K | Current report (foreign issuer) | Sep 22, 2026 | Sep 22, 2026 |
| 6-K | Current report (foreign issuer) | Sep 18, 2026 | Sep 18, 2026 |
| 6-K | Current report (foreign issuer) | Sep 1, 2026 | Sep 1, 2026 |
| 6-K | Current report (foreign issuer) | Aug 31, 2026 | Aug 31, 2026 |
| 6-K | Current report (foreign issuer) | Aug 31, 2026 | Aug 31, 2026 |
| 6-K | Current report (foreign issuer) | Aug 28, 2026 | Aug 28, 2026 |
All 1000 Kazia Therapeutics Limited. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.